Drug intelligence / Profile preview

Whole tooth allograft

Development stage: Phase 2
Lead developer: Jordan University Hospital
Administration: Topical

Overview

Whole tooth allografts (WTA) are biological grafting materials derived from extracted human teeth, specifically processed for use in alveolar ridge preservation. Developed by researchers at Jordan University Hospital, WTA is being evaluated as a sustainable and scalable alternative to autogenous bone grafts. The material is placed into the extraction socket to prevent the natural resorption of the alveolar ridge that occurs after tooth loss, thereby maintaining sufficient bone volume for subsequent dental implant placement or other prosthetic rehabilitations. WTA acts as an osteoconductive scaffold, providing structural support and potentially biological signals to promote bone healing and volume maintenance.

Other names: Whole tooth allograftsAllogenic dentin graft

Beyond the preview

Go deeper on Whole tooth allograft.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Whole tooth allograft.

Explore the full profile